Literature DB >> 34843000

Repolarization in systemic sclerosis: a meta-analysis.

Yehuda Wexler1, Udi Nussinovitch2.   

Abstract

OBJECTIVES: Systemic sclerosis (SSc) is a rare connective tissue disease characterized by immune dysregulation, vascular damage, and increased deposition of extracellular matrix. In SSc, cardiac manifestations are common and account for 14% of deaths. Numerous studies have examined electrocardiographic findings in SSc patients yielding conflicting reports regarding QTc duration. We conducted a systematic review and meta-analysis of existing studies to investigate whether QTc duration may aid in diagnosis and risk stratification of SSc patients.
METHODS: Two electronic databases (PubMed and Embase) were searched for case-control and cohort studies assessing QTc duration in SSc patients published before March 1, 2021. A random-effects model was used to meta-analyze the results, and included studies were tested for heterogeneity. Linear regression was performed to determine correlations between comorbidities, and QTc duration.
RESULTS: Ninety-six studies, abstracts, and posters were identified. After abstract review and duplicate removal, 23 manuscripts remained. After application of the inclusion and exclusion criteria, 10 studies remained which were quantitatively analyzed. The weighted mean QTc was found to be 422.21 ms for SSc patients and 411.43 ms for control subjects. A significant increase in QTc duration among SSc patients was found, with a standardized mean difference of 0.59 (p < 0.01, 95% CI 0.27-0.92). No significant correlation was found between underlying traits and QTc values. Substantial heterogeneity was found between the studies (I2 = 83%, p < 0.01).
CONCLUSION: A significant increase in QTc duration is observed in SSc patients, though the absolute prolongation is not extreme. Therefore, the clinical utility of this finding is unclear and merits large prospective observations. Key Points • A statistically significant prolongation of the QTc interval exists in patients with systemic sclerosis. • Absolute QTc differences between healthy controls and scleroderma patients are not extreme, and, as such, may be of limited clinical utility. • When assessing the underlying traits of systemic sclerosis patients, no statistically significant correlations were found between underlying parameters and QTc duration.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  ECG; QT; QTc; Repolarization; Scleroderma; Systemic sclerosis

Mesh:

Year:  2021        PMID: 34843000     DOI: 10.1007/s10067-021-05996-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  In systemic sclerosis prolonged QTc interval is associated with reduced exercise tolerance.

Authors:  Antonietta Gigante; Edoardo Rosato; Marta Liberatori; Liborio Sardo; Marcello Di Paolo; Paolo Marinelli; Giuseppe Barilaro; Paolo Palange; Antonio Amoroso; Luigi Tubani
Journal:  Int J Cardiol       Date:  2015-11-09       Impact factor: 4.164

2.  Relationships between electrocardiographic and echocardiographic findings in systemic sclerosis (scleroderma).

Authors:  S Morelli; A Sgreccia; L Ferrante; C Barbieri; M L Bernardo; C Perrone; P De Marzio
Journal:  Int J Cardiol       Date:  1996-12-06       Impact factor: 4.164

3.  Electrocardiography in 110 patients with systemic sclerosis: a cross-sectional comparison with population-based controls.

Authors:  A Nordin; L Björnådal; A Larsson; E Svenungsson; K Jensen-Urstad
Journal:  Scand J Rheumatol       Date:  2014-01-07       Impact factor: 3.641

Review 4.  Cardiac manifestations in systemic sclerosis.

Authors:  Sevdalina Lambova
Journal:  World J Cardiol       Date:  2014-09-26

5.  Prolonged Tp-e interval and Tp-e/QT correlates well with modified Rodnan skin severity score in patients with systemic sclerosis.

Authors:  Sercan Okutucu; Ugur Nadir Karakulak; Hakan Aksoy; Cengiz Sabanoglu; Vedat Hekimsoy; Levent Sahiner; Ergun Baris Kaya; Ali Akdogan; Giray Kabakci; Kudret Aytemir; Lale Tokgozoglu; Ali Oto
Journal:  Cardiol J       Date:  2016-05-13       Impact factor: 2.737

6.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

7.  Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction.

Authors:  B H Bulkley; R L Ridolfi; W R Salyer; G M Hutchins
Journal:  Circulation       Date:  1976-03       Impact factor: 29.690

8.  The cardiac conduction system in progressive systemic sclerosis. Clinical and pathologic features of 35 patients.

Authors:  R L Ridolfi; B H Bulkley; G M Hutchins
Journal:  Am J Med       Date:  1976-09       Impact factor: 4.965

9.  Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma.

Authors:  W P Follansbee; E I Curtiss; T A Medsger; V D Steen; B F Uretsky; G R Owens; G P Rodnan
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

10.  Survival and causes of death in 366 Hungarian patients with systemic sclerosis.

Authors:  L Czirják; G Kumánovics; C Varjú; Z Nagy; A Pákozdi; Z Szekanecz; G Szucs
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.